Table 3.
Characteristic | HR | 95% CI | p value |
---|---|---|---|
Age (ABC diagnosis), (≥ 60 vs. < 60 years) | 1.16 | 0.96–1.40 | 0.130 |
Treatment line of fulvestrant (4th or more vs. 3rd vs. 1st and 2nd) | 1.02 | 0.90–1.16 | 0.754 |
ABC diagnosis to fulvestrant use (≥ 3 vs. < 3 years) | 0.18 | 0.14–0.24 | < 0.001 |
Prior palliative chemotherapy (yes vs. no) | 1.37 | 1.12–1.67 | 0.002 |
PgR (positive vs. negative) | 1.20 | 0.95–1.53 | 0.131 |
Histological or nuclear grade | |||
(2 vs. 1) | 1.28 | 1.04–1.59 | 0.021 |
(3 vs. 1) | 1.78 | 1.39–2.28 | < 0.001 |
OS overall survival, HR hazard ratio, CI confidence interval, ABC advanced breast cancer, PgR, progesterone receptor